Major depressive disorder (MDD) is a prevalent mood disorder that is associated with differential prefrontal brain expression patterns 1 . Treatment of MDD includes a variety of biopsychosocial approaches. In medical practice, antidepressant drugs are the most common treatment for depressive episodes, and they are among the most prescribed medications in North America 2, 3 . Although antidepressants are clearly effective, particularly for moderate to severe depressive episodes, there is variability in how individuals respond to antidepressant treatment. Failure to respond has individual, economic and social consequences for patients and their families 4 . Several lines of evidence demonstrate that genes are regulated through the activity of microRNAs (miRNAs), which act as fine-tuners and on-off switches of gene expression [5] [6] [7] . Here we report on complementary studies using postmortem human brain samples, cellular assays and samples from clinical trials of patients with depression and show that miR-1202, a miRNA specific to primates and enriched in the human brain, is differentially expressed in individuals with depression. Additionally, miR-1202 regulates expression of the gene encoding metabotropic glutamate receptor-4 (GRM4) and predicts antidepressant response at baseline. These results suggest that miR-1202 is associated with the pathophysiology of depression and is a potential target for new antidepressant treatments.
We assessed miRNA expression in the ventrolateral prefrontal cortex (PFC) of individuals with depression compared to psychiatrically healthy controls ( Supplementary Table 1 ). Statistical analysis, using Benjamini-Hochberg correction for multiple testing and corrected P values <0.05, identified miR-1202 as the most dysregulated miRNA, with decreased expression in depressed brains (Fig. 1a) , findings that we validated by quantitative RT-PCR (qRT-PCR) (Fig. 1b,c) . According to miRBase 8 , miR-1202 has very little evolutionary conservation.
To better characterize this miRNA, we first investigated in silico its expression and conservation among species. Using the hg19 University of California, Santa Cruz Genome Browser assembly 9,10 , we investigated the conservation of miR-1202 in 100 animal genomes. Whereas miRNAs are generally well conserved across species 7 , miR-1202 is present only in humans and other primates ( Supplementary  Fig. 1) . In contrast, we found that let-7a1, a miRNA known to be well conserved 11 , is encoded in 95 of 100 genomes investigated. We subsequently investigated miR-1202 conservation experimentally by measuring expression in brains of six representative animal species. We extracted miRNA from human, cynomolgus monkey, rhesus monkey, rat, mouse and chicken brains. We found higher expression of miR-1202 in human brain as compared to cynomolgus and rhesus monkey brains, and we did not detect its expression in brains of the other species ( Fig. 1d) . To investigate tissue specificity, we measured miR-1202 levels in ten human tissues. Although we detected some expression of miR-1202 in all tissues, expression was considerably enriched in the brain (Fig. 1e) . These findings suggest a key role for miR-1202 in cognitive processes that are unique to primates, particularly humans.
Gene targets of miR-1202 were predicted using five miRNA target prediction databases [12] [13] [14] [15] [16] . We only considered those predicted by all five databases, and we then crossreferenced these predicted genes with PFC mRNA microarray expression libraries from a subset of these subjects [17] [18] [19] [20] . As there is an expected inverse relationship between miRNAs and their mRNA targets, we selected only genes expressed and upregulated in the PFC of subjects with depression ( Supplementary Table 2 ). Notably, all of the selected genes are linked with neurological processes associated with the pathogenesis of MDD. Next, we quantified the expression of the predicted gene targets of miR-1202, using qRT-PCR, in subjects previously used for microarray analysis. Five genes were upregulated in the PFC of subjects with depression ( Fig. 1f) . miR-1202 levels correlated negatively with the expression of GRM4, but not with that of the other predicted miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment genes ( Fig. 1g) . Additionally, we found an increase of GRM4 protein expression levels that correlated with the increased mRNA levels ( Supplementary Fig. 2 ). GRM4 is expressed throughout the brain and is localized pre-and postsynaptically, where it modulates glutamatergic, dopaminergic, GABAergic and serotonergic neurotransmission 21 . In recent years, GRM4 has been implicated in the regulation of anxiety-related behaviors [21] [22] [23] , and it is seen as an attractive target for drug discovery and development 24 .
To test the external validity of our findings, we measured the expression of miR-1202 and GRM4 in a larger, independent sample composed of PFC tissue from control subjects and individuals with depression. Additionally, we included a third group, individuals with depression who had a history of antidepressant use and positive antidepressant toxicology at the time of death ( Supplementary Table 3 ). In line with previous findings, miR-1202 expression was decreased in subjects with depression as compared to controls. Notably, we also found a difference in miR-1202 expression between subjects with depression depending on whether they had a history of antidepressant use ( Fig. 1h) . Consistent with our previous findings, GRM4 was upregulated in depressed brains, whereas there was no difference in GRM4 expression between controls and individuals with depression and antidepressant history. Nevertheless, subjects with depression showed differential expression of GRM4 dependent on antidepressant history ( Fig. 1i) . Furthermore, we observed a negative correlation between miR-1202 and GRM4 expression levels ( Fig. 1j) . Finally, in order to explore the effects of anxiety, we investigated PFC tissue from individuals who at the time of their death met criteria for a major anxiety disorder and were of similar age to the individuals with MDD and control subjects. However, the vast majority of these individuals died by suicide, and, as expected, they also met criteria for MDD. Our results show differential expression of miR-1202 and GRM4 in PFC tissue from these individuals as compared to controls, although the effects were stronger in the group of subjects with MDD alone( Supplementary  Fig. 3) . These findings suggest a relationship between miR-1202, GRM4, MDD and antidepressant treatment in humans.
To experimentally confirm the interaction between miR-1202 and GRM4, we performed functional experiments in human embryonic kidney cells (HEK 293). We selected HEK 293 cells after screening miR-1202 and GRM4 expression in six different cell lines ( Supplementary Table 4 ). HEK 293 cells showed no endogenous expression of miR-1202 and relatively high levels of GRM4 and thus were an ideal model for our tests. We examined whether npg overexpression of miR-1202 affects the expression of GRM4. We transfected cells with an miR-1202 mimic (Online Methods), a scramble control or a mock vehicle for 24 h. We found decreased GRM4 levels after transfection of miR-1202 mimic in HEK 293 cells but no effects on GRM4 expression after treatment with the scramble or vehicle controls ( Fig. 2a) . We then tested whether neutralizing miR-1202 affected GRM4 using miRNA target protectors (Online Methods). We treated cells with miR-1202 mimic and either a target protector or a scramble control for 24 h. We specifically designed the target protectors to interfere with the two predicted binding sites of miR-1202 in the 3′ untranslated region of the GRM4 gene (Supplementary Fig. 4) . Cotransfection of miR-1202 mimic with either target protector (TP1 or TP2) in HEK 293 cells reversed GRM4 levels to baseline (Fig. 2b) . There were no effects on GRM4 expression levels after treatment with either target protector alone, scramble or vehicle controls (Supplementary Fig. 5) . These results confirm an interaction between miR-1202 and GRM4.
Subsequently, we tested whether miR-1202 responds to changes in the expression of GRM4. We performed functional experiments using GRM4 agonist and antagonist in human neural progenitor cells (NPCs). Human NPCs showed relatively high levels of miR-1202 after 1 week of differentiation and expressed GRM4 ( Supplementary Table 4 and Supplementary Fig. 6 ). We used the GRM4 agonist (2S)-2-amino-4-phosphonobutanoic acid (l-AP4) and antagonist 2-methyl-Ophosphonoserine (MSOP) at nontoxic concentrations based on results from the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Supplementary Fig. 7) . NPCs were treated for 7 d with l-AP4, MSOP or a no-drug control. Treatment with l-AP4 reduced GRM4 expression, whereas MSOP treatment increased expression ( Fig. 2c) . Consistent with our hypothesis, miR-1202 expression was upregulated after l-AP4 treatment and downregulated after MSOP treatment (Fig. 2d) . These results suggest a bidirectional interaction between miR-1202 and GRM4.
There has been increased interest in the potential role of miRNAs as molecular intermediaries of therapeutic response. Given our postmortem results, we hypothesized that miR-1202 may mediate response to antidepressant treatment. We examined the effects of antidepressants on miR-1202 by treating NPCs with two commonly prescribed antidepressants, citalopram or imipramine, or a no-drug control. NPCs display a serotonergic phenotype (Supplementary Fig. 8a,b) . We treated cells for 24 h (acute treatment) or for 15 d (chronic treatment) at nontoxic concentrations (Supplementary Fig. 9 ). We found no effect of acute treatment with either drug on miR-1202 or GRM4 expression ( Fig. 2e,f) , but we found an upregulation of miR-1202 after chronic treatment with either imipramine or citalopram (Fig. 2g) . Chronic treatment with either antidepressant reduced GRM4 mRNA expression ( Fig. 2h) , findings that we also observed at the protein level using imaging and immunocytochemistry assays ( Supplementary  Fig. 10 ). We did not observe these effects when treating cells with medications that do not have direct effects on serotonin or the serotonin transporter (SERT) (lithium and valproate). Furthermore, through knockdown experiments, we found that the increase in miR-1202 expression after chronic treatment with citalopram or imipramine is dependent on SERT and the reuptake blockade needed for antidepressant action (Supplementary Fig. 11a-g) . Finally, to investigate whether the effects of chronic treatment were due to a global miRNA dysregulation, we measured the expression levels of several miRNAs known to be ubiquitously expressed, but we found no differences in the expression of any of these miRNAs after chronic antidepressant treatment (Supplementary Fig. 12) . These findings indicate a relationship between miR-1202 and antidepressant treatment response.
On the basis of our in vitro results, we explored the regulation of miR-1202 in patients with MDD according to antidepressant treatment. We measured blood levels of miR-1202 in treatment-naive patients with MDD and psychiatrically healthy control subjects (Supplementary Table 5 ). We treated patients with citalopram as previously reported 25 (Fig. 3a) . In line with previous findings, we found a decrease of miR-1202 expression in patients with depression (Fig. 3b) . We classified subjects with depression into remitters and nonresponders on the basis of changes in their Hamilton Rating Scale for Depression (HAM-D) scores. Notably, a comparison npg between groups revealed that the miR-1202 dysregulation, at baseline, was driven by the remitter group. There was a decrease in miR-1202 expression in the remitter group as compared to the other groups but no difference in its expression between nonresponders and controls ( Fig. 3c) . Moreover, the remitter group showed increased miR-1202 levels after 8 weeks of treatment (Fig. 3d) , whereas we found no difference in miR-1202 levels in nonresponders or controls (Fig. 3e,f) . Furthermore, change in depression severity negatively correlated with change in miR-1202 expression (Fig. 3g) . These findings confirm a relationship between peripheral miR-1202 expression and citalopram treatment response in patients with MDD. To our knowledge, this is the first study to report, in humans, a consistent miRNA dysregulation in postmortem brain tissue and blood samples from individuals with MDD. Additionally, and most notably, our results suggest the possibility that changes in miR-1202 expression levels could predict citalopram treatment response. These results may have implications in the search for biomarkers and predictors of treatment response in MDD and suggest that miR-1202 could be potentially used as a biomarker of treatment prediction or response. Although it is unclear how miRNA levels in the periphery and the brain interact during antidepressant treatment, it can be hypothesized that miRNAs may actively cross the blood-brain barrier 26 . Alternatively, miRNA changes observed in blood might reflect neuroendocrine or neuroimmune responses elicited by the brain. Indeed, several miRNAs appear to modulate both immune and neuronal processes and may mediate the interaction between these systems 27 . Our findings and results from others support the hypothesis that targeting miRNAs directly could be therapeutically beneficial.
Together, our results suggest that the dysregulation of miR-1202 in postmortem brain and peripheral blood is associated with the pathophysiology of MDD. Our results postulate miR-1202 as a biomarker of MDD and a predictor of antidepressant treatment response. This study highlights the role of miRNAs in neuropsychiatric disorders and provides further steps toward the development of early diagnostic tools, preventive strategies and effective pharmacological treatment for mood disorders.
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